The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2017 | Understanding the mechanisms of venetoclax and ibrutinib resistance
We need to understand the mechanisms of drug resistance in order to prevent it, in addition to informing subsequent treatment decisions. In this interview, Constantine Tam, MD, FRACP, FRCPA, of Peter MacCallum Cancer Centre, Melbourne, Australia, discusses our current knowledge of the mechanisms of resistance to venetoclax and ibrutinib. He highlights how, interestingly, the usual mutation of the primary therapeutic target has not been found in venetoclax resistant patients thus far. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
